ACADIA Pharmaceuticals (ACAD) Receives a Buy from JMP Securities

JMP Securities analyst Jason Butler reiterated a Buy rating on ACADIA Pharmaceuticals (ACADResearch Report) today and set a price target of $23.00. The company’s shares closed yesterday at $16.62.

According to TipRanks, Butler is an analyst with an average return of -4.9% and a 41.42% success rate. Butler covers the Healthcare sector, focusing on stocks such as Concert Pharma, Applied Molecular Transport, and Precigen.

In addition to JMP Securities, ACADIA Pharmaceuticals also received a Buy from Cowen & Co.’s Ritu Baral in a report issued yesterday. However, on August 5, Citigroup downgraded ACADIA Pharmaceuticals (NASDAQ: ACAD) to a Hold.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $28.06 and a one-year low of $12.24. Currently, ACADIA Pharmaceuticals has an average volume of 2.72M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Read More on ACAD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More